Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Growth Hormones (August 2016)

Posted by Matt Breese on Aug 26, 2016

Find me on:

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access by channel shows how payer pharmacy benefits cover HGH products. Commercial and health exchange formulary access is more restrictive than it was last quarter, while Medicare Part D formularies experience a slight lift in unrestricted lives.

reality-check-hgh-aug.png

Source: MMIT data as of Q3 2016

Trends: One trend is the imminence of long-acting biobetters in the growth hormone market, which expects to seize significant market share from existing daily recombinant products. However, some research shows that safety may become more of a factor in the success of long-acting biologics, as safety notes are expected to be exclusive to a single LAGH treatment. Finally, new innovation in technology reveals that a portable device could produce biologic drugs "on-the-go", which could make waves in the HGH manufacturer arena.

To read the full Reality Check on human growth hormones with key findings on clinical characteristics, MS drug market access and payer coverage, please click on the button below: 

MMIT-RC_Featured_Image.png

View Reality Check

Topics: Market Access, Data & Analytics, Branding & Marketing